Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2011, Article ID 820816, 8 pages
http://dx.doi.org/10.1155/2011/820816
Review Article

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder

Urodynamic Urology Unit, Department of Urology, Medical School, University of Patras, 26500 Patra, Greece

Received 26 February 2011; Accepted 13 April 2011

Academic Editor: Yasuhiko Igawa

Copyright © 2011 Anastasios Athanasopoulos and Konstantinos Giannitsas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Hashim and P. Abrams, “Overactive bladder: an update,” Current Opinion in Urology, vol. 17, no. 4, pp. 231–236, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. K.-E. Andersson, “Antimuscarinic mechanisms and the overactive detrusor: an update,” European Urology, vol. 59, no. 3, pp. 377–386, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. O. Yamaguchi, “Antimuscarinics and overactive bladder: other mechanism of action,” Neurourology and Urodynamics, vol. 29, no. 1, pp. 112–115, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. D. Giglio and G. Tobin, “Muscarinic receptor subtypes in the lower urinary tract,” Pharmacology, vol. 83, no. 5, pp. 259–269, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. E. Andersson and C. R. Chappie, “Oxybutynin and the overactive bladder,” World Journal of Urology, vol. 19, no. 5, pp. 319–323, 2001. View at Google Scholar · View at Scopus
  6. S. De Wachter and J. J. Wyndaele, “Intravesical oxybutynin: a local anesthetic effect on bladder C afferents,” Journal of Urology, vol. 169, no. 5, pp. 1892–1895, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. G. W. Davila, “Transdermal oxybutynin: a new treatment for overactive bladder,” Expert Opinion on Pharmacotherapy, vol. 4, no. 12, pp. 2315–2324, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. A. A. Siddiqui, C. M. Perry, and L. J. Scott, “Oxybutynin extended-release: a review of its use in the management of overactive bladder,” Drugs, vol. 64, no. 8, pp. 885–912, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Wefer, M. C. Truss, and U. Jonas, “Tolterodine: an overview,” World Journal of Urology, vol. 19, no. 5, pp. 312–318, 2001. View at Google Scholar · View at Scopus
  10. H. Madersbacher and G. Mürtz, “Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic),” World Journal of Urology, vol. 19, no. 5, pp. 324–335, 2001. View at Google Scholar · View at Scopus
  11. D. Robinson and L. Cardozo, “The emerging role of solifenacin in the treatment of overactive bladder,” Expert Opinion on Investigational Drugs, vol. 13, no. 10, pp. 1339–1348, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Maniscalco, D. Singh-Franco, W. R. Wolowich, and R. Torres-Colón, “Solifenacin succinate for the treatment of symptoms of overactive bladder,” Clinical Therapeutics, vol. 28, no. 9, pp. 1247–1272, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. C. R. Chapple, “Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder,” Expert Opinion on Investigational Drugs, vol. 13, no. 11, pp. 1493–1500, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. F. Haab, “Darifenacin for the treatment of overactive bladder,” Women's Health, vol. 1, pp. 331–343, 2005. View at Google Scholar
  15. K. Hofner, M. Oelke, S. Machtens, and V. Grünewald, “Trospium chloride—an effective drug in the treatment of overactive bladder and detrusor hyperreflexia,” World Journal of Urology, vol. 19, no. 5, pp. 336–343, 2001. View at Google Scholar · View at Scopus
  16. E. S. Rovner, “Trospium chloride in the management of overactive bladder,” Drugs, vol. 64, no. 21, pp. 2433–2446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. C. Michel, “Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome,” Expert Opinion on Pharmacotherapy, vol. 9, no. 10, pp. 1787–1796, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. T. Hanawa, C. Tsuchiya, N. Endo et al., “Formulation study of intravesical oxybutynin instillation solution with enhanced retention in bladder,” Chemical and Pharmaceutical Bulletin, vol. 56, no. 8, pp. 1073–1076, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. C. Diokno, R. A. Appell, P. K. Sand et al., “Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial,” Mayo Clinic Proceedings, vol. 78, no. 6, pp. 687–695, 2003. View at Google Scholar · View at Scopus
  20. R. A. Appell, P. Sand, R. Dmochowski, R. Anderson, and N. Zinner, “Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study,” Mayo Clinic Proceedings, vol. 76, no. 4, pp. 358–363, 2001. View at Google Scholar
  21. P. Sand, N. Zinner, D. Newman et al., “Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study,” British Journal of Urology International, vol. 99, no. 4, pp. 836–844, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. L. T. Pizzi, A. Talati, E. Gemmen, N. V. Dahl, T. J. Bunz, and P. K. Sand, “Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study,” PharmacoEconomics, vol. 27, no. 4, pp. 329–339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. D. R. Staskin and D. Robinson, “Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder,” Expert Opinion on Pharmacotherapy, vol. 10, no. 18, pp. 3103–3111, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. G. Novara, A. Galfano, S. Secco et al., “A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder,” European Urology, vol. 54, no. 4, pp. 740–764, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. F. Guest, D. Abegunde, and F. J. Ruiz, “Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria,” Clinical Drug Investigation, vol. 24, no. 6, pp. 305–321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Nilvebrant, B. Hallén, and G. Larsson, “Tolterodine A new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data,” Life Sciences, vol. 60, no. 13-14, pp. 1129–1136, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Salvatore, M. Serati, and P. Bolis, “Tolterodine for the treatment of overactive bladder,” Expert Opinion on Pharmacotherapy, vol. 9, no. 7, pp. 1249–1255, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. P. Abrams, R. Freeman, C. Anderström, and A. Mattiasson, “Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder,” British Journal of Urology, vol. 81, no. 6, pp. 801–810, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Giannitsas, P. Perimenis, A. Athanasopoulos, K. Gyftopoulos, G. Nikiforidis, and G. Barbalias, “Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity,” European Urology, vol. 46, no. 6, pp. 776–782, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. H. Madersbacher and G. Mürtz, “Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic),” World Journal of Urology, vol. 19, no. 5, pp. 324–335, 2001. View at Google Scholar · View at Scopus
  31. H. Madersbacher, M. Halaska, R. Voigt, S. Alloussi, and K. Höfner, “A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence,” British Journal of Urology International, vol. 84, no. 6, pp. 646–651, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. K. P. Jünemann, M. Halaska, T. Rittstein et al., “Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder,” European Urology, vol. 48, no. 3, pp. 478–482, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. H. Madersbacher and G. Mürtz, “Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic),” World Journal of Urology, vol. 19, no. 5, pp. 324–335, 2001. View at Google Scholar · View at Scopus
  34. S. H. Alloussi, G. Murtz, J. Seibold et al., “Antimuscarincs in children: is its use in children evidence-based?” International Urogynecology Journal, vol. 21, supplement 1, p. 428, 2010, abstract 292. View at Google Scholar
  35. K. S. Lee, H. W. Lee, M. S. Choo et al., “Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data,” British Journal of Urology International, vol. 105, no. 11, pp. 1565–1570, 2010. View at Google Scholar
  36. P. Dwyer, C. Kelleher, J. Young et al., “Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study,” Neurourology and Urodynamics, vol. 27, no. 6, pp. 540–547, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. N. Zinner, K. C. Kobashi, U. Ebinger et al., “Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy,” International Journal of Clinical Practice, vol. 62, no. 11, pp. 1664–1674, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. P. Abrams and S. Swift, “Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis,” European Urology, vol. 48, no. 3, pp. 483–487, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. P. Herbison, J. Hay-Smith, G. Ellis, and K. Moore, “Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review,” British Medical Journal, vol. 326, no. 7394, pp. 841–844, 2003. View at Google Scholar · View at Scopus
  40. C. R. Chapple, R. Martinez-Garcia, L. Selvaggi et al., “A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial,” European Urology, vol. 48, no. 3, pp. 464–470, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. L. Cardozo, E. Heßdörfer, R. Milani et al., “Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial,” British Journal of Urology International, vol. 102, no. 9, pp. 1120–1127, 2008. View at Publisher · View at Google Scholar · View at PubMed
  42. M. M. Karram, M. R. Toglia, S. R. Serels, M. Andoh, A. Fakhoury, and S. Forero-Schwanhaeuser, “Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial,” Urology, vol. 73, no. 1, pp. 14–18, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. N. Zinner, M. Gittelman, R. Harris, J. Susset, A. Kanellos, and S. Auerbach, “Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial,” Journal of Urology, vol. 171, no. 6 I, pp. 2311–2315, 2004. View at Publisher · View at Google Scholar
  44. L. Cardozo, V. Mirone, C. Gratzke, and M. Marberger, “Extended-release trospium chloride 60 mg—a new once-daily medication for the treatment of overactive bladder syndrome,” European Urological Review, vol. 5, no. 1, pp. 3–6, 2010. View at Google Scholar
  45. V. Nitti, M. Wiatrak, L. Kreitman, and D. Lipsitz, Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB)Q results of a phase 2 trial. Paper presented at International Continence Society Montreal, Canada, 2005.
  46. C. Chapple, P. Van Kerrebroeck, A. Tubaro et al., “Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder,” European Urology, vol. 52, no. 4, pp. 1204–1212, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. S. A. Kaplan, T. Schneider, J. E. Foote, Z. Guan, M. Carlsson, and J. Gong, “Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial,” British Journal of Urology International, vol. 107, no. 9, pp. 1432–1440, 2011. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Herschorn, S. Swift, Z. Guan et al., “Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial,” British Journal of Urology International, vol. 105, no. 1, pp. 58–66, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. J.-J. Wyndaele, E. R. Goldfischer, J. D. Morrow et al., “Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study,” International Journal of Clinical Practice, vol. 63, no. 4, pp. 560–567, 2009. View at Publisher · View at Google Scholar
  50. C. Chapple, V. Khullar, Z. Gabriel, and J. A. Dooley, “The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis,” European Urology, vol. 48, no. 1, pp. 5–26, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. C. R. Chapple, V. Khullar, Z. Gabriel, D. Muston, C. E. Bitoun, and D. Weinstein, “The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis,” European Urology, vol. 54, no. 3, pp. 543–562, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. C. R. Chapple, V. Khullar, Z. Gabriel, D. Muston, C. E. Bitoun, and D. Weinstein, “The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis,” European Urology, vol. 54, no. 3, pp. 543–562, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. L. P. W. Witte, W. M. C. Mulder, J. J. M. C. H. De La Rosette, and M. C. Michel, “Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?” Current Opinion in Urology, vol. 19, no. 1, pp. 13–19, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. R. Millard, J. Tuttle, K. Moore et al., “Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity,” Journal of Urology, vol. 161, no. 5, pp. 1551–1555, 1999. View at Publisher · View at Google Scholar
  55. Y. E. Yarker, K. L. Goa, and A. Fitton, “Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability,” Drugs & Aging, vol. 6, no. 3, pp. 243–262, 1995. View at Google Scholar · View at Scopus
  56. P. D. Meek, S. D. Evang, M. Tadrous, D. Roux-Lirange, D. M. Triller, and B. Gumustop, “Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials,” Digestive Diseases and Sciences, vol. 56, no. 1, pp. 7–18, 2011. View at Publisher · View at Google Scholar · View at PubMed
  57. G. Kay, T. Crook, L. Rekeda et al., “Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects,” European Urology, vol. 50, no. 2, pp. 317–326, 2006. View at Publisher · View at Google Scholar · View at PubMed
  58. R. B. Lipton, K. Kolodner, and K. Wesnes, “Assessment of cognitive function of the elderly population: effects of darifenacin,” Journal of Urology, vol. 173, no. 2, pp. 493–498, 2005. View at Publisher · View at Google Scholar · View at PubMed
  59. G. G. Kay and U. Ebinger, “Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin,” International Journal of Clinical Practice, vol. 62, no. 11, pp. 1792–1800, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. D. Staskin, G. Kay, C. Tannenbaum et al., “Trospium chloride is undetectable in the older human central nervous system,” Journal of the American Geriatrics Society, vol. 58, no. 8, pp. 1618–1619, 2010. View at Publisher · View at Google Scholar · View at PubMed
  61. B. Malhotra, K. Gandelman, R. Sachse, N. Wood, and M. C. Michel, “The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine,” Current Medicinal Chemistry, vol. 16, no. 33, pp. 4481–4489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Olshansky, U. Ebinger, J. Brum, M. Egermark, A. Viegas, and L. Rekeda, “Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants ≥50 years,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 13, no. 4, pp. 241–251, 2008. View at Publisher · View at Google Scholar · View at PubMed
  63. D. B. Serra, M. B. Affrime, M. P. Bedigian et al., “QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder,” Journal of Clinical Pharmacology, vol. 45, no. 9, pp. 1038–1047, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. R. M. Hussain, K. Hartigan-Go, S. H. L. Thomas, and G. A. Ford, “Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence,” British Journal of Clinical Pharmacology, vol. 41, no. 1, pp. 73–75, 1996. View at Google Scholar · View at Scopus
  65. B. K. Malhotra, P. Glue, K. Sweeney, R. Anziano, J. Mancuso, and P. Wicker, “Thorough QT study with recommended and supratherapeutic doses of tolterodine,” Clinical Pharmacology and Therapeutics, vol. 81, no. 3, pp. 377–385, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. Y. Homma and O. Yamaguchi, “A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder,” International Journal of Urology, vol. 16, no. 5, pp. 499–506, 2009. View at Publisher · View at Google Scholar · View at PubMed
  67. B. Malhotra, N. Wood, R. Sachse, and K. Gandelman, “Thorough QT study of the effect of fesoterodine on cardiac repolarization,” International Journal of Clinical Pharmacology and Therapeutics, vol. 48, no. 5, pp. 309–318, 2010. View at Google Scholar · View at Scopus
  68. M. C. Michel, U. Wetterauer, M. Vogel, and J. J. De La Rosette, “Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study,” Drug Safety, vol. 31, no. 6, pp. 505–514, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. C. L. G. Sears, C. Lewis, K. Noel, T. S. Albright, and J. R. Fischer, “Overactive bladder medication adherence when medication is free to patients,” Journal of Urology, vol. 183, no. 3, pp. 1077–1081, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. A. O. D'Souza, M. J. Smith, L. A. Miller, J. Doyle, and R. Ariely, “Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan,” Journal of Managed Care Pharmacy, vol. 14, no. 3, pp. 291–301, 2008. View at Google Scholar · View at Scopus
  71. R. Peeker, G. Samsioe, J. Kowalski, A.-S. Andersson, and A. Bergqvist, “A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden,” Scandinavian Journal of Urology and Nephrology, vol. 44, no. 3, pp. 138–146, 2010. View at Publisher · View at Google Scholar · View at PubMed
  72. C. R. Chapple, A. Fianu-Jonsson, M. Indig et al., “Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg,” European Urology, vol. 52, no. 4, pp. 1195–1203, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. F. Haab and D. Castro-Diaz, “Persistence with antimuscarinic therapy in patients with overactive bladder,” International Journal of Clinical Practice, vol. 59, no. 8, pp. 931–937, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. J. S. Benner, M. B. Nichol, E. S. Rovner et al., “Patient-reported reasons for discontinuing overactive bladder medication,” British Journal of Urology International, vol. 105, no. 9, pp. 1276–1282, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. C. R. Chapple, M. T. Rosenberg, and F. J. Brenes, “Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome,” British Journal of Urology International, vol. 104, no. 7, pp. 960–967, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. M. B. Chancellor, N. Zinner, K. Whitmore et al., “Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study,” Clinical Therapeutics, vol. 30, no. 10, pp. 1766–1781, 2008. View at Publisher · View at Google Scholar · View at PubMed
  77. J.-J. Wyndaele, E. R. Goldfischer, J. D. Morrow, J. Gong, L.-J. Tseng, and M.-S. Choo, “Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study,” British Journal of Urology International, vol. 107, no. 4, pp. 603–611, 2011. View at Publisher · View at Google Scholar · View at PubMed
  78. A. Athanasopoulos and P. Perimenis, “Efficacy of the combination of an α1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction,” Expert Opinion on Pharmacotherapy, vol. 6, no. 14, pp. 2429–2433, 2005. View at Publisher · View at Google Scholar · View at PubMed
  79. A. Athanasopoulos, “Antimuscarinics and bladder outlet obstruction: from a contraindication to an indication?” Neurourology and Urodynamics, vol. 29, supplement 1, pp. S46–S50, 2010. View at Publisher · View at Google Scholar · View at PubMed
  80. A. Athanasopoulos, D. Mitropoulos, K. Giannitsas, and P. Perimenis, “Safety of anticholinergics in patients with benign prostatic hyperplasia,” Expert Opinion on Drug Safety, vol. 7, no. 4, pp. 473–479, 2008. View at Publisher · View at Google Scholar · View at PubMed
  81. C. Chapple, “Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia,” Current Opinion in Urology, vol. 20, no. 1, pp. 43–48, 2010. View at Publisher · View at Google Scholar · View at PubMed
  82. C. Füllhase, R. Soler, C. Gratzke, M. Brodsky, G. J. Christ, and K. E. Andersson, “Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction,” British Journal of Urology International, vol. 106, no. 2, pp. 287–293, 2010. View at Publisher · View at Google Scholar · View at PubMed
  83. G. Conte-Santos, M. Rebbassa-Llull, L. Soriano-Burrull et al., “Study of safety and urodynamic characteriztion of treatment with tamsulosin, tolderodine and tamsulosin plus tolderodine, in men with LUTS,” European Urology, vol. 8, no. 4, p. 237, 2009, abstract 468. View at Google Scholar
  84. B. T. Blake-James, A. Rashidian, Y. Ikeda, and M. Emberton, “The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis,” British Journal of Urology International, vol. 99, no. 1, pp. 85–96, 2007. View at Publisher · View at Google Scholar · View at PubMed
  85. G. Novara, A. Galfano, V. Ficarra, and W. Artibani, “Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review,” European Urology, vol. 50, no. 4, pp. 675–683, 2006. View at Publisher · View at Google Scholar · View at PubMed